Novel coronavirus infection
Conditions
Interventions
Conventional therapies:Patients with COVID-19 are treated with symptomatic treatment, antiviral therapy, immunotherapy, respiratory support, and intensive care.
Conventional treatment is combined with oxymethacoumarin:On the basis of symptomatic treatment, antiviral therapy, immunotherapy, respiratory support, and intensive care, patients were treated with hy
Sponsors
People's Hospital of Ningxia Hui Autonomous Region
Eligibility
Sex/Gender
All
Age
14 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Be over 14 years old, and with no gender limitation; 2.Patients confirmed with novel coronavirus infection, using the nasopharyngeal swab; 3.The level of hyaluronic acid in serum is greater than 100ng/ml.
Exclusion criteria
Exclusion criteria: 1.Pations with severe non-infectious pulmonary disease, including lung tumor,pulmonary atelectasis,pulmonary embolism,pulmonary eosinophilic infiltration,pulmonary vasculitis; 2.Patients who has severe liver and kidney dysfunction, for example; ALT and AST exceed the upper limit of normal value by more than 10 times; the serum creatinine exceed the upper limit of normal value by more than 1.5 times; the total bilirubin exceed the upper limit of normal value by more than 2 times; 3.Patients with biliary obstruction; 4.Other patients that investigators consider they do not suitable for this trial, or the investigators believe that there may be any conditions that increase the risk of participants or interfere with the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hyaluronan levels;SARS-CoV-2 viral load; | — |
Secondary
| Measure | Time frame |
|---|---|
| Lymphocyte restoration condition;Changes in inflammatory factor levels (Interleukin-6, Ferritin, C-reactive protein, Erythrocyte Sedimentation Rate, and Procalcitonin); | — |
Countries
China
Contacts
Public ContactZhuan Bing
People's Hospital of Ningxia Hui Autonomous Region
Outcome results
None listed